Menu Search
Equities

Dawnrays Pharmaceutical (Holdings) Ltd

2348:HKG.HZ

Dawnrays Pharmaceutical (Holdings) Ltd

Actions
  • Price (HKD)1.11
  • Today's Change-0.01 / -0.89%
  • Shares traded668.00k
  • 1 Year change-0.89%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Dawnrays Pharmaceutical (Holdings) Ltd's revenues fell -9.90% from 1.28bn to 1.15bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 358.06m to 326.00m, a -8.95% decrease.
Gross margin56.58%
Net profit margin51.92%
Operating margin62.23%
Return on assets14.74%
Return on equity18.54%
Return on investment17.79%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Dawnrays Pharmaceutical (Holdings) Ltd fell by 44.86m. However, the company earned 338.40m from its operations for a Cash Flow Margin of 29.40%. In addition the company generated 2.07m cash from financing while 387.57m was spent on investing.
Cash flow per share0.4668
Price/Cash flow per share2.38
Book value per share2.40
Tangible book value per share2.00
More ▼

Balance sheet in CNYView more

Dawnrays Pharmaceutical (Holdings) Ltd has a Debt to Total Capital ratio of 5.44%, a higher figure than the previous year's 0.00%.
Current ratio3.40
Quick ratio3.04
Total debt/total equity0.0576
Total debt/total capital0.0544
More ▼

Growth rates in CNY

SmartText is unavailable
Div yield(5 year avg)5.54%
Div growth rate (5 year)2.00%
Payout ratio (TTM)19.59%
EPS growth(5 years)2.52
EPS (TTM) vs
TTM 1 year ago		27.38
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.